Skip to main content

 Scientific publications

Anthracyclines in the treatment of patients with early breast cancer.

Authors : Guarneri V, de Azambuja E
Year : 2022
Journal : ESMO Open
Volume : 7
Pages : 100461

Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial.

Authors : Franzoi MA, Procter M, Twelves C, Ponde N, Eiger D, Emond O, Clark E, Parlier D, Guillaume S, Reaby L, de Azambuja E, Bines J
Year : 2022
Journal : Ecancermedicalscience
Volume : 16
Pages : 1379

Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study.

Authors : Nader-Marta G, Debien V, Eiger D, Tsourti Z, Caparica R, Kassapian M, Napoleone S, Hultsch S, Korde L, Wang Y, Chumsri S, Pritchard KI, Untch M, Bellet-Ezquerra M, Dornelles Rosa D, Moreno-Aspitia A, Piccart M, Dafni U, de Azambuja E
Year : 2022
Journal : Br J Cancer
Volume : 127
Pages : 1799-1807

Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy.

Authors : Lambertini M, Fielding S, Loibl S, Janni W, Clark E, Franzoi MA, Fumagalli D, Caballero C, Arecco L, Salomoni S, Ponde NF, Poggio F, Kim HJ, Villarreal-Garza C, Pagani O, Paluch-Shimon S, Ballestrero A, Del Mastro L, Piccart M, Bines J, Partridge AH, de Azambuja E
Year : 2022
Journal : J Natl Cancer Inst
Volume : 114
Pages : 1117-1126

Tumour infiltrating lymphocytes and ductal carcinoma in situ: The art of thinking counterintuitively.

Authors : Salgado R, Fineberg S, De Caluwe A, de Azambuja E
Year : 2022
Journal : Eur J Cancer
Volume : 168
Pages : 138-140

Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY

Authors : Gelber Rd, Wang XV, Cole BF, Cameron D, Cardoso F, Tjan-Heijnen V, Krop I, Loi S, Salgado R, Kiermaier A, Frank E, Fumagalli D, Caballero C, de Azambuja E, Procter M, Clark E, Restuccia E, Heeson S, Bines J, Loibl S, Piccart-Gebhart M
Year : 2022
Journal : Eur J Cancer
Volume : 166
Pages : 219-228

Adding a platinum agent to neoadjuvant chemotherapy for triple-negative breast cancer: the end of the debate.

Authors : Poggio F, Tagliamento M, Ceppi M, Bruzzone M, Conte B, Fregatti P, Punie K, de Azambuja E, Del Mastro L, Lambertini M
Year : 2022
Journal : Ann Oncol
Volume : 33
Pages : 347-349

De novo Metastatic Breast Cancer Arising in Young Women: Review of the Current Evidence.

Authors : Conte B, Soldato D, Razeti MG, Fregatti P, de Azambuja E, Schettini F, Prat A, Del Mastro L, Lambertini M
Year : 2022
Journal : Clin Breast Cancer
Volume : 22
Pages : 78-87

Correction to: Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub‑analysis of the ALTTO trial (BIG 2‑06; NCCTG (Alliance) N063D).

Authors : Pondé N, Agbor-Tarh D, Dal Lago L, Korde LA, Hilbers F, Jackisch C, Werner O, Gelber Rd, Jatoi A, Dueck AC, Moreno-Aspitia A, Sotiriou C, de Azambuja E, Piccart M
Year : 2022
Journal : Breast Cancer Res Treat
Volume : 191
Pages : 225

Tumor Cellularity and Infiltrating Lymphocytes (CelTIL) as a Survival Surrogate in HER2-Positive Breast Cancer.

Authors : Chic N, Luen SJ, Nuciforo P, Salgado R, Fumagalli D, Hilbers F, Wang Y, de Azambuja E, Làng I, Di Cosimo S, Saura C, Huober J, Prat A, Loi S
Year : 2022
Journal : J Natl Cancer Inst
Volume : 114(3)
Pages : 467-70

Perspectives on emerging technologies, personalised medicine, and clinical research for cancer control in Latin America and the Caribbean.

Authors : Werutsky G, Barrios CH, Cardona AF, Albergaria A, Valencia A, Ferreira CG, Rolfo C, de Azambuja E, Rabinovich GA, Sposetti G, Arrieta O, Dienstmann R, Rebelatto TF, Denninghoff V, Aran V, Cazap E
Year : 2021
Journal : Lancet Oncol
Volume : 22
Pages : e488-e500

Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer.

Authors : Condorelli M, Bruzzone M, Ceppi M, Ferrari A, Grinshpun A, Hamy AS, de Azambuja E, Carrasco E, Peccatori FA, Di Meglio A, Paluch-Shimon S, Poorvu PD, Venturelli M, Rousset-Jablonski C, Senechal C, Livraghi L, Ponzone R, De Marchis L, Pogoda K, Sonnenblick A, Villarreal-Garza C, Córdoba O, Teixeira L, Clatot F, Punie K, Graffeo R, Dieci MV, Pérez-Fidalgo JA, Duhoux FP, Puglisi F, Ferreira AR, Blondeaux E, Peretz-Yablonski T, Caron O, Saule C, Ameye L, Balmaña J, Partridge AH, Azim HA, Demeestere I, Lambertini M
Year : 2021
Journal : ESMO Open
Volume : 6
Pages : 100300

ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.

Authors : Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im SA, Krug D, Kunz WG, Loi S, Lorca FP, Ricke J, Robson M, Rugo HS, Saura C, Schmid P, Singer CF, Spanic T, Tolaney SM, Turner NC, Curigliano G, Loibl S, Paluch-Shimon S, Harbeck N
Year : 2021
Journal : Ann Oncol

Tolerability and toxicity of trastuzumab or trastuzumab?+?lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D).

Authors : Pondé N, Agbor-Tarh D, Dal Lago L, Korde LA, Hilbers F, Jackisch C, Werner O, Gelber Rd, Jatoi A, Dueck AC, Moreno-Aspitia A, Sotiriou C, de Azambuja E, Piccart-Gebhart M
Year : 2021
Journal : Breast Cancer Res Treat
Volume : 185
Pages : 107-116

Integrated molecular and immune phenotype of HER2-positive breast cancer and response to neoadjuvant therapy: a NeoALTTO exploratory analysis.

Authors : Pizzamiglio S, Ciniselli CM, Triulzi T, Gargiuli C, De Cecco L, de Azambuja E, Fumagalli D, Sotiriou C, Harbeck N, Izquierdo M, Nuciforo P, Huober J, Cappelletti V, Cinieri S, Piccart-Gebhart M, Daidone MG, Pruneri G, Colombo MP, Tagliabue E, Verderio P, Di Cosimo S
Year : 2021
Journal : Clin Cancer Res

Response to letter entitled: Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials.

Authors : Agostinetto E, Ceppi M, Bruzzone M, Lambertini M, de Azambuja E
Year : 2021
Journal : Eur J Cancer
Volume : 155
Pages : 303-306

Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis.

Authors : Caparica R, Bruzzone M, Agostinetto E, Franzoi MA, Ceppi M, Radosevic-Robin N, Penault-Llorca F, Willard-Gallo K, Loi S, Salgado R, de Azambuja E
Year : 2021
Journal : Breast
Volume : 59
Pages : 183-192

Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.

Authors : Venet D, Rediti M, Maetens M, Fumagalli D, Brown DN, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov VF, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart-Gebhart M, Loi S, Rothé F, Sotiriou C
Year : 2021
Journal : Clin Cancer Res
Volume : 27
Pages : 5607-5618

EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours.

Authors : Le Rhun E, Guckenberger M, Smits M, Dummer R, Bachelot T, Sahm F, Galldiks N, de Azambuja E, Berghoff AS, Metellus P, Peters S, Hong YK, Winkler F, Schadendorf D, Van den Bent M, Seoane J, Stahel R, Minniti G, Wesseling P, Weller M, Preusser M
Year : 2021
Journal : Ann Oncol
Volume : 32
Pages : 1332-1347

Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study.

Authors : van Walle L, Punie K, Van Eycken E, de Azambuja E, Wildiers H, Duhoux FP, Vuylsteke P, Barbeaux A, Van Damme N, Verhoeven D
Year : 2021
Journal : ESMO Open
Volume : 6
Pages : 100207